Novartis to acquire AveXis for $8.7 billion

The acquisition will add AveXis top drug to its repertoire of drugs, which has a significant market in the U.S. for spinal muscular atrophy.

On Monday, Switzerland-based healthcare giant Novartis announced its $8.7 billion deal to acquire AveXis; Novartis will pay $218 per share in a cash for every AveXis’ share.

The successful acquisition will add AveXis’s top drug hopeful, to its basket of drugs, which targets spinal muscular atrophy. In the U.S., the drug is designated as a significant breakthrough in therapies.

Having just agreed to sell a stake in its consumer healthcare joint venture for $13 billion to GlaxoSmithKline, Novartis is flush with cash.


Categories: Creativity, Economy & Finance, Entrepreneurship, HR & Organization, Regulations & Legal, Strategy

Tags: , , , , , , , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: